These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 8181862

  • 1. Adoptive immunotherapy of established tumors. Acquisition of radioresistance by tumor-specific T cells after passive transfer into tumor-bearing recipients.
    Dunn PL, North RJ.
    Int J Cancer; 1994 May 15; 57(4):592-7. PubMed ID: 8181862
    [Abstract] [Full Text] [Related]

  • 2. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
    Dye ES, North RJ.
    J Leukoc Biol; 1984 Jul 15; 36(1):27-37. PubMed ID: 6234371
    [Abstract] [Full Text] [Related]

  • 3. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.
    Dye ES, North RJ.
    J Exp Med; 1981 Oct 01; 154(4):1033-42. PubMed ID: 6457075
    [Abstract] [Full Text] [Related]

  • 4. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.
    North RJ.
    Cancer Immunol Immunother; 1984 Oct 01; 16(3):175-81. PubMed ID: 6231095
    [Abstract] [Full Text] [Related]

  • 5. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.
    Mills CD, North RJ.
    J Exp Med; 1983 May 01; 157(5):1448-60. PubMed ID: 6189937
    [Abstract] [Full Text] [Related]

  • 6. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 7. Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor.
    Dunn PL, North RJ.
    J Leukoc Biol; 1991 Apr 15; 49(4):388-96. PubMed ID: 1900523
    [Abstract] [Full Text] [Related]

  • 8. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
    Dye ES.
    J Immunol; 1986 Feb 15; 136(4):1510-5. PubMed ID: 3080526
    [Abstract] [Full Text] [Related]

  • 9. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.
    Wang LX, Shu S, Plautz GE.
    Cancer Res; 2005 Oct 15; 65(20):9547-54. PubMed ID: 16230420
    [Abstract] [Full Text] [Related]

  • 10. Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.
    Hines DL.
    Cancer Immunol Immunother; 1989 Oct 15; 28(4):241-7. PubMed ID: 2495177
    [Abstract] [Full Text] [Related]

  • 11. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE, Zachary DT, Osband ME.
    Int J Cancer; 1995 May 16; 61(4):580-6. PubMed ID: 7759164
    [Abstract] [Full Text] [Related]

  • 12. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors.
    Awwad M, North RJ.
    Cancer Res; 1990 Apr 15; 50(8):2228-33. PubMed ID: 2317810
    [Abstract] [Full Text] [Related]

  • 13. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.
    Plautz GE, Inoue M, Shu S.
    Cell Immunol; 1996 Aug 01; 171(2):277-84. PubMed ID: 8806798
    [Abstract] [Full Text] [Related]

  • 14. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX, Chen BG, Plautz GE.
    J Immunol; 2002 Sep 15; 169(6):3314-20. PubMed ID: 12218152
    [Abstract] [Full Text] [Related]

  • 15. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells.
    North RJ.
    J Exp Med; 1986 Nov 01; 164(5):1652-66. PubMed ID: 2945892
    [Abstract] [Full Text] [Related]

  • 16. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.
    Rosenstein M, Eberlein TJ, Rosenberg SA.
    J Immunol; 1984 Apr 01; 132(4):2117-22. PubMed ID: 6607955
    [Abstract] [Full Text] [Related]

  • 17. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.
    Hornung RL, Longo DL, Bowersox OC, Kwak LW.
    J Natl Cancer Inst; 1995 Sep 06; 87(17):1289-96. PubMed ID: 7544833
    [Abstract] [Full Text] [Related]

  • 18. Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression.
    Dye ES, North RJ.
    Transplantation; 1984 Jun 06; 37(6):600-5. PubMed ID: 6427998
    [Abstract] [Full Text] [Related]

  • 19. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 20. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
    Nagy E, Baral E, Kangas L, Berczi I.
    Anticancer Res; 1997 Mar 15; 17(2A):1083-8. PubMed ID: 9137453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.